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A targeted high-throughput sequencing (HTS) panel test for clinical diagnostics 
requires careful consideration of the inclusion of appropriate diagnostic-grade genes, the 
ability to detect multiple types of genomic variation with high levels of analytic sensitivity 
and reproducibility, and variant interpretation by a multi-disciplinary team (MDT) in the 
context of the clinical phenotype. We have sequenced 2,396 index patients using the 
ThromboGenomics HTS panel test of diagnostic-grade genes known to harbour variants 
associated with rare bleeding, thrombotic or platelet disorders (BTPD). The molecular 
diagnostic rate was determined by the clinical phenotype, with an overall rate of 49.2% 
for all thrombotic, coagulation, platelet count and function disorder patients and a rate of 
3.2% for patients with unexplained bleeding disorders characterized by normal 
hemostasis test results. The MDT classified 745 unique variants, including copy number 
and intronic variants, as Pathogenic, Likely Pathogenic or Variants of Uncertain 
Significance. Half (50.9%) of these variants are novel and 41 unique variants were 
identified in 7 genes recently found to be implicated in BTPD. Inspection of canonical 
hemostasis pathways identified 29 patients with evidence of oligogenic inheritance. A 
molecular diagnosis has been reported for 894 index patients providing evidence that 
introducing an HTS genetic test is a valuable addition to laboratory diagnostics in patients 


















Inherited bleeding, thrombotic and platelet disorders (BTPD) are a heterogeneous 
group of rare disorders caused by DNA variants in a large number of loci. The most 
common bleeding disorders are von Willebrand Disease, affecting up to 0.01% of the 
population, and Hemophilia A and B, which together affect 0.01% of males.1 There are 
no accurate estimates of the prevalence of the remaining rare inherited bleeding 
disorders, although registry data suggest the prevalence being <0.001%.2 Venous 
thrombosis has an overall annual incidence of less than 1 in 1,000, but it is rare in the 
pediatric population, with rates of approximately 1 in 100,000, indicative of possible 
environmental and lifestyle effects in adult patients.3 To obtain a conclusive molecular 
diagnosis requires attendance at multiple outpatient consultations for a large portion of 
patients with an assumed diagnosis of a rare inherited BTPD.  
 
The genetic architecture of inherited BTPDs is well determined, but new genes 
continue to be identified. To date there are close to 100 diagnostic-grade genes (hereafter 
TIER1 genes) associated with coagulation, thrombotic and platelet disorders. Since 
validation of the ThromboGenomics HTS test4, 33 TIER1 genes, including recently 
discovered BTPD genes, have been added to the HTS test, increasing the clinical utility. 
Others have reported on similar gene panel tests or used whole exome sequencing to 
identify DNA variants causing inherited BTPDs5-10. Most studies used patients with 
uniform clinical phenotypes, but all on relatively small numbers of patients (<160 index 
patients), preventing firm conclusions about the clinical utility of such tests. The diagnostic 
rates obtained in these studies cannot be compared as all focused on different sets of 
genes (with a subset of TIER1 genes, and also inclusion of ‘research’ genes), used 
different patient inclusion criteria and variant classification was not standardized as is now 
recommended.11 
 
Here we report on the results obtained with the ThromboGenomics HTS test for 
2,396 index patients categorized into five classes of disorders based on the appended 





count, platelet function, coagulation and unexplained bleeding. Variant interpretation, by 
a multi-disciplinary team (MDT), determined the contribution of variants in TIER1 genes 
to the observed phenotypes thereby providing insights in the clinical utility of HTS testing 
for different categories of patients. We also comment on the standardization of variant 
interpretation and how the reporting of a conclusive molecular diagnosis has immediately 
impacted on clinical management. Finally, due to the large number of patients tested, we 
are able to highlight the clinical importance of detecting copy number and deep intronic 





The 2,396 index patients were either referrals for the ThromboGenomics test or 
patients who joined the PANE and VIBB studies (Supplemental Table 1). Clinical and 
laboratory phenotypes were recorded using HPO terms as described.4,13 Further details 
of the study participants, including institutional review board or research ethics committee 
information are in the Supplemental Information. 
 
ThromboGenomics referrals for diagnostic testing of inherited BTPDs 
Samples with clinical and laboratory phenotype information from 1,608 index patients with 
a known or suspected diagnosis of inherited BTPD, according to criteria described 
(Supplemental Information),4 were recruited by clinicians in 72 UK and 46 non-UK 
hospitals (Supplemental Figure 1).  
 
PANE: Preoperative screening for mild bleeding risk  
A total of 212 patients, identified through preoperative assessment of bleeding risk at 
Maastricht University Medical Centre, were recruited and underwent a full hematological 
assessment including extensive laboratory testing for hemostasis parameters 







VIBB: Vienna Bleeding Biobank   
A total of 599 patients referred to the Hematology and Hemostaseology specialist tertiary 
referral centre in Vienna for assessment of a mild to moderate bleeding disorder were 
recruited and subjected to a full hematological assessment, including extensive laboratory 
testing for hemostasis parameters (Supplemental Table 2).16 
 
ThromboGenomics HTS test   
The ThromboGenomics HTS test sample preparation and sequencing protocols 
are as described with minor modifications (Supplemental Information).4 The content of 
the test has been reversioned twice since first described to include additional (mostly 
recently discovered) TIER1 genes. ThromboGenomics version 2 (TG.V2) and version 3 
(TG.V3) include 80 and 96 genes, respectively (Supplemental Table 3). TIER1 genes are 
curated and approved by the Scientific and Standardization Committee on Genomics in 
Thrombosis and Hemostasis (SSC-GinTH) of the International Society on Thrombosis 
and Haemostasis (ISTH) (https://www.isth.org/page/GinTH_GeneLists). For TG.V3, 
probes for 10,000 common single nucleotide variants (SNVs) were included to estimate 
relatedness and ancestry. Automated bioinformatics analysis pipeline methods, including 
variant calling, are described in the Supplemental Information. 
 
Variant prioritisation and interpretation 
Variants were annotated and prioritized for interpretation using the analytical 
process as reported4 based on the predicted effect in the curated transcript, presence in 
the Human Gene Mutation Database17 or in a curated set of known pathogenic variants 
(Supplemental Information) and the minor allele frequency (MAF) in the Exome 
Aggregation Consortium (ExAC) and Genome Aggregation (gnomAD) databases.18 On a 
patient-by-patient basis, DNA variants passing filtering were prioritized and interpreted by 
a MDT in the context of the appended HPO terms, clinical information and family history. 
Reported variants were characterized as Pathogenic, Likely Pathogenic and Variants of 
Uncertain Significance alongside a decision of the likely contribution of each variant to 
the patients phenotype. The MDT made use of Congenica's diagnostic decision support 





in the form of research reports for return to referring clinicians. For all samples sequenced 
using TG.V2, variant interpretation was performed according to guidelines agreed by the 
members of the ThromboGenomics MDT (criteria in Supplemental Table 4 and details of 
MDT process in Supplemental Information). In 2017, the UK Association of Clinical 
Genomic Science published best practice guidelines for variant interpretation based on 
the earlier reported American College of Medical Genetics and Genomics (ACMG) 
guidelines.11 Sapienta software implemented ACMG guidelines from release 1.7 (January 
2018), allowing rapid variant interpretation following these guidelines. This updated 
system was applied for variant interpretation of all samples sequenced using TG.V3. 
Table 1 summarizes the main differences in panel content, methods, analysis and 




Patient inclusion criteria and phenotypes 
A total of 2,396 index patients and 156 samples from relatives and carriers were 
tested using the ThromboGenomics HTS test (Supplemental Table 1). The largest group 
of 1,608 index patients and 18 referrals for hemophilia carrier status were referred by 
specialist tertiary centres for diagnostic testing. To better appreciate the clinical utility of 
the HTS test we also included 193 and 595 index patients from the PANE and VIBB 
single-centre studies.  
 
Based on the clinical and laboratory phenotypes of all patients, a total of 7,341 
HPO terms were appended. HPO terms and clinical information were used to categorize 
all patients into five broad disease classes; thrombotic (n=284), platelet count (n=335), 
platelet function (n=430), coagulation (n=728) and unexplained bleeding (n=619) (Figure 
1A). The ThromboGenomics referrals included patients of all five classes, while the 
majority of the PANE (80.3%) and VIBB (59.5%) patients are classed as unexplained 
bleeding. 
Most of the patients categorized to the thrombotic class were referred because of 





protein C anticoagulation pathway’ (Figure 1B). Patients with platelet count disorders 
were generally referred due to (macro)thrombocytopenia. Platelet function abnormalities 
were diverse, including defects in aggregation, reduced platelet membrane protein 
expression (particularly GPIb/IX/V and GPIIb/IIIa) and reduced granule secretion. 
Coagulation defects included patients with reduced VWF levels or abnormal coagulation 
parameters of the intrinsic, extrinsic and common pathways. HPO terms coding abnormal 
phenotypes outside the blood system were appended to 41 (1.7%) of patients. These 
terms related to eyes (ocular albinism), hearing (deafness), skeletal (abnormal radius, 
joint disorders) and kidney (functional insufficiency). Across the three study groups 619 
patients with bleeding symptoms and normal hemostasis test results were classed as 
unexplained bleeding (Figure 1B). Over half (51.2%) of the patients in this class were 
characterized by the presence of both spontaneous and trauma-related bleeding 
symptoms, a similar distribution as found for the coagulation and platelet function disease 
class (Supplemental Figure 2). Chronic mild thrombocytopenia is generally not 
accompanied by spontaneous bleeding.19 However, 65.1% of the patients in the platelet 
count class presented with spontaneous bleeding, strongly suggesting an enrichment of 
‘thrombocytopenia with bleeding’ patients. 
 
Performance of the ThromboGenomics HTS test 
The previously reported validation of the ThromboGenomics HTS test (TG.V1) 
used 296 samples from patients, with and without previously known disease causing 
variants, sequenced for 63 TIER1 genes.4 Here we sequenced 1,333 and 1,063 index 
patient samples with the TG.V2 and TG.V3 tests targeting 80 and 96 TIER1 genes, with 
a region of interest of 0.222 Mb and 0.275 Mb respectively (Table 1). Since validation, the 
analysis method for calling SNVs and short (<50 base pair (bp)) insertion/deletions 
(indels) has undergone minor modifications; however, the detection of CNVs has been 
substantially improved.20 In short, sequencing read depth is computed over 500 bp 
elements, to improve the sensitivity for the detection of shorter CNVs, and an optimized 
reference set of data obtained from 10 samples has been generated, using genetically 
unrelated individuals (Supplemental Information). Despite the increase of the region of 





with 99.99% and 99.98% of the region of interest with a read depth exceeding 30x for 
TG.V2 and TG.V3 tests, respectively. For each sample, an average of 146.7 and 190.9 
SNVs, 9.4 and 11.2 indels and 0.20 and 0.21 CNVs were identified by the TG.V2 and 
TG.V3 tests, respectively. The proportions of variant types identified did not differ 
between test versions (Supplemental Figure 3). For all samples, an average 4.5 variants 
were prioritized for interpretation by the MDT (Supplemental Table 1).    
 
Diagnostic rates and validation of recently discovered TIER1 genes  
Prioritized variants were reviewed by the MDT in the context of the disease 
incidence, variant frequency, assigned HPO terms and family history. Variants were 
reported with pathogenicity and the contribution to the patients phenotype (full or partial). 
Variants for recessive BTPDs were reported if present in the homozygous or compound 
heterozygous states. Variants of Uncertain Significance were reported if the MDT 
predicted a future Likely Pathogenic status with additional evidence from cosegregation 
and functional studies. Screening of 2,396 index patients resulted in an overall molecular 
diagnostic rate of 37.3% by reporting a total of 1,031 variants in 894 index patients (Figure 
2A, Supplemental Table 5). Most reported variants (81.9%) were rare (<0.01%) or absent 
in gnomAD (Supplemental Figure 4). There was a marked difference in diagnostic yield 
between the five classes; thrombotic, 48.9%; platelet count 47.8%; platelet function 
26.1%; coagulation disorders 63.6% and unexplained bleeding 3.2% (Figure 2A). For 
patients with thrombotic and coagulation disorders, 68.7% and 70.6% of reported variants 
were known variants that had previously been associated with disease, while for the 
patients with platelet count and function disorders this proportion was lower; 44.4% and 
28.4% respectively (Figure 2B). We reason that this difference reflects the fact that 
cataloging of pathogenic variants for coagulation disorders (especially von Willebrand 
disease and Hemophilia A and B) began over three decades ago, whilst the majority of 
TIER1 genes for platelet disorders have only been identified over the past decade. Of the 
335 patients within the platelet count class, 29 were referred under a working diagnosis 
of ‘immune thrombocytopenia refractory to treatment’. In 7 of these patients, variants were 






The implementation of the criteria of the ACMG guidelines, instead of our ‘in-
house’ criteria (Supplemental Table 4), impacted on variant interpretation for patients 
tested using TG.V3. On comparing the ThromboGenomics cohort samples sequenced 
and analyzed using either TG.V2 or TG.V3 (PANE and VIBB samples were sequenced 
using only TG.V2 and TG.V3 respectively), there was minimal difference in the total 
number of reported variants for each of the five classes of patients (Supplemental Figure 
5A). However, for all disease classes, an interpretation shift from Likely Pathogenic to 
Variant of Uncertain Significance was noted (Supplemental Figure 5B). This change in 
variant interpretation was mainly explained by novel missense variants (Supplemental 
Figure 6). For patients tested using TG.V2, variants that were not known as disease 
associated were often deemed as Likely Pathogenic by the MDT. On introduction of the 
ACMG guidelines, these novel missense variants did not reach the threshold for 
designation as Likely Pathogenic and thus were labeled as Variants of Uncertain 
Significance. Prior to submission, all variants have been reanalyzed according to ACMG 
guidelines, using the latest versions of variant databases, including the 
ThromboGenomics database, and results from co-segregation studies (Supplementary 
Table 5, column ‘Reinterpretation 2019’).  
 
The genes with reported variants in index patients are ranked in Figure 3. For the 
thrombotic, platelet count and coagulation disease classes, a quarter of patients had 
variants reported in just one gene, PROS1, MYH9 and VWF, respectively. The fourth 
quarter of patients for each disease class had reported variants in at least 6 genes. All 
reported variants per patient are summarized in Supplemental Table 5 and have been 
submitted to the ClinVar database.21        
 
Since TG.V1, 17 TIER1 genes associated with BTPD have been included in TG.V2 
and a further 16 more TIER1 genes in TG.V3. In addition to introducing known and 
recently discovered genes, those with new modes of inheritance were added 
(Supplemental Table 3). Diagnostic reports for 41 patients have been issued with variants 






Copy number variation, deep intronic variants and oligogenic findings. 
The analytical pipeline for the identification of CNVs has been modified with 
improved quality scoring and visualization tools. Overall, CNVs were reported in 40 
patients, predicted to affect single exons (n=11), multiple exons (n=15) or whole genes 
(n=14) (Supplemental Table 5). Manual inspection of reads revealed the presence of 
complex CNVs, including an inversion with breakpoints in introns 26 and 27 of DIAPH1 
resulting in an in-frame deletion of exon 26, and an inversion flanked by two deletions 
within F8 causing severe hemophilia A (Supplemental Figure 7).22  
 
Aside from the core dinucleotide splice sites at the 5’ and 3’ of introns, the lack of 
reliable prediction tools makes it difficult to determine the likely functional consequences 
of potential splicing altering variants. Outside the SnpEff annotated splice regions (8 bp), 
intronic variants were only prioritized if previously associated with disease. A deep intronic 
homozygous ITGA2B variant identified in one index patient with Glanzmann 
Thrombasthenia was validated using platelet RNA expression studies confirming 
alternative splicing and the absence of normal ITGA2B transcript (Supplemental Figure 
8). These functional data, together with co-segregation analysis in the pedigree of the 
index patient, resulted in a reclassification of this ITGA2B variant from Variant of 
Uncertain Significance to Likely Pathogenic. 
 
Of the 894 index patients where variants were reported, 772 had a single reported 
variant while 122 had at least two reported variants. Most patients with two variants have 
a recessive disease, but for 29 patients the reported variants were in two or more genes. 
For most of these examples, the variants identified were within first or second order 
interactors in the known canonical hemostasis pathways (Supplemental Table 6). For the 
thrombotic and coagulation classes, we identified 11 (3.9%) and 13 (1.8%) patients with 
oligogenic variants, respectively (Figure 4).  
 
Incidental findings 
By sequencing a large number of patients for the TIER1 genes underlying known 





referred for hemophilia carrier testing or known to have reduced factor levels, we 
identified carriership of Likely Pathogenic variants in F8 or F9. In addition, in two patients 
we identified a heterozygous deletion of the RBM8A gene. A heterozygous RBM8A loss-
of function variant (generally a deletion), if accompanied by a low frequency non-coding 
regulatory variant on the alternate allele, results in thrombocytopenia with absent radius 
syndrome.23 These incidental secondary findings were reported to the referring clinician 
as they are actionable with respect to family planning. In contrast, sex chromosome 





We evaluated the performance of a targeted HTS panel test for TIER1 genes in 
over 2,500 subjects drawn from three distinct groups; (1) patients with a high likelihood 
of having an inherited BTPD, (2) patients undergoing an extended preoperative 
assessment for bleeding risk and (3) patients with a bleeding disorder of unknown etiology 
referred to a tertiary referral centre. Using HPO coding of clinical and laboratory 
phenotypes alongside clinical information, patients were assigned to one of five diseases 
classes; thrombotic, platelet count, platelet function, coagulation or unexplained bleeding. 
DNA samples were sequenced with the ThromboGenomics HTS test and prioritized 
variants reviewed and classified by an MDT and reported to referring clinicians. The 
resulting data were used to assess the effectiveness of the HTS test, analytical pipeline 
and MDT variant interpretation in generating a conclusive molecular diagnosis. For 1,777 
patients of the thrombotic, coagulation and platelet count or function disease class, 
variants were reported for half (49.2%). In contrast, variants were reported for 3.2% of the 
619 index unexplained bleeding patients with normal hemostasis test results. Overall, 
20.1% of reported variants were Variants of Uncertain Significance that require additional 
evidence including estimation of variant odds ratios using the results from large 
genotyped cohort studies, functional testing and cosegregation analysis. These data 
illustrate the diagnostic yield obtained when applying the ThromboGenomics test for 





Screening patients with the TG.V2 and TG.V3 HTS test presented several 
improvements compared to the TG.V1 test. Adding more TIER1 genes on TG.V2 and 
TG.V3 supported the molecular diagnosis of 41 patients and important genotype-
phenotype association were observed for recently discovered BTPD genes such as 
DIAPH122, ETV624, GFI1B25, GNE26,27 and RASGRP228 or for the alternative mode of 
inheritance recently reported for GP1BB.29 In comparison to TG.V1, the detection of 
CNVs was optimized, resulting in the detection of CNVs in 40 patients, including 
previously unobserved deletions in 13 genes, indicating CNVs as an important variant 
class for all categories of BTPDs. In addition, 2 novel duplications, 1 novel inversion and 
a complex CNV were also reported. Nevertheless, the optimized ExomeDepth method is 
sensitive to variable read depths, has a minimum resolution and cannot detect inversions 
or predict the location of duplicated regions. The introduction of a split-read or read-pair 
CNV calling method, alongside the ExomeDepth analysis method, may further improve 
CNV detection in the future.  
 
Previously, Sanger sequencing of most BTPD genes was performed with primer 
sets flanking intron/exon boundaries and therefore, the frequency of non-coding or silent 
variants, aside from those disrupting the immediate splice site (<+/- 8 bp from the exon 
boundary), that are associated with BTPDs is unknown. With the use of HTS, deep 
intronic variants have been identified and apparent silent variants in BTPD genes have 
been shown to alter splicing.30-33 Variants disrupting transcription regulatory motifs 
located in gene promoters and enhancer regions have also been associated with BTPDs, 
and with the recent mapping of endothelial and blood cell specific enhancers, it is likely 
that more variants located in these regions will be identified as associated with disease 
in the near future.34-36 Nevertheless, due to the challenges in interpretation of non-coding 
variants we have only targeted and prioritized intronic and regulatory variants if previously 
associated with disease. Therefore, a research analysis of novel deep intronic, silent and 
likely regulatory variants detected is required, and such studies are best performed using 






 A diagnostic HTS platform requires careful selection of diagnostic-grade TIER1 
genes. The decision to include a gene to the BTPD TIER1 list is made by the GinTH SSC 
of the ISTH. The designation of genes for diagnostic reporting involved the review of 
associated literature to evaluate if a gene is associated with disease in more than three 
independent pedigrees with convincing cosegregation data or in less than three 
pedigrees, but with strong functional evidence (mouse models or cell/protein studies) in 
addition to cosegregation data. In the future, this task will also be coordinated by the NIH 
supported Hemostasis/Thrombosis Clinical Domain Working Group in close partnership 
with the ISTH and ASH expert working groups.37  
 
Our results indicate that when screening large number of patients with a HTS test, 
half (50.1%) of unique reported variants are novel and following ACMG guidelines for 
TG.V3, the majority (76.1%) of novel unique missense variants were reported as Variants 
of Uncertain Significance (Supplemental Figure 6). International initiatives for sharing of 
sequence data generated for BTPD patients and the sequencing of the genomes or 
exomes of large prospective population cohorts, like the UK Biobank, the Million Veteran 
Program and the 100,000 Genomes Project will lead to statistically robust approaches for 
the functional labelling of DNA variants, including the Variants of Uncertain Significance 
reported in this study. 38-40 
 
These data provide evidence of how a molecular diagnosis influences the clinical 
management and counselling of patients and their close relatives. In 30 patients, variants 
were reported in the ANKRD26, ETV6 and RUNX1 genes leading to counseling and 
follow up due to the increased risk of hematological malignancies. These findings are 
associated with an important ethical debate regarding predictive testing in these genes41. 
It is therefore advisable to inform clinicians and patients about the presence of genes 
associated with malignancies in a panel and to provide the possibility of an opt out choice. 
As for whole genome or exome sequencing clinical testing strategies, virtual subpanels 
can be used to independently analyze genes only associated with bleeding, thrombotic 
or platelet disorders (with and without inclusion of leukemic risk genes). In 7 patients with 





variants likely causing their condition. In six of these cases, the identification of a Variant 
of Uncertain Significance has prompted follow-up studies in the probands and their 
relatives to obtain additional evidence for pathogenicity. Finally, in 24 patients with 
thrombotic or coagulation disorders, we reported variants in two or more TIER1 genes. 
We postulate that defects in hemostasis are due to the disruption of two interacting 
proteins in the known canonical pathways. These results of a large single study, further 
extend the reports of possible oligogenic architecture for thrombotic and coagulation. 
Together these justify further functional and genetic follow-up studies to provide patients 
with a molecular diagnosis and better estimates of risk to offspring. 
 
We report the results of the largest gene panel sequencing study of patients with 
suspected inherited BTPDs. We included 619 index patients with an unexplained bleeding 
disorder characterized by normal hemostasis test results, and as per our hypothesis, we 
observed a low diagnostic rate for this group. It is possible that unknown genes are 
responsible or that the propensity of bleeding in these patients is the result of the 
aggregation of a large number of small effects emanating from common variants at 
hundreds of loci which are modifying the overall effectiveness of the hemostasis system. 
Estimation of polygenic risk scores has recently been reported for several common 
diseases such as coronary artery disease, type 2 diabetes and breast cancer42-45.  
 
In patients with a known or suspected disease etiology, a molecular diagnosis was 
not discovered in half (50.8%) of patients. Future versions of the ThromboGenomics 
panel will include additional genes as they are identified and designated TIER1 status. 
However, this is unlikely to significantly increase the diagnostic rate as hundreds of genes 
are predicted to be currently unknown. Others have shown that reanalysis of negative 
clinical exome sequencing data at 1-3 years increased the diagnostic rate by 10% due to 
new evidence for gene causality and candidate variants not available during the initial 
analysis.46 Such evidences have emerged due to the curation of disease variants, by 
ClinVar and the Human Gene Mutation Database, and the availability of large exome and 
genome sequencing datasets (ExAC and gnomAD). To further increase diagnostic rates 





will provide more accurate estimates of the rareness of potential pathogenic variants,47 
alongside the development of novel genotype-phenotype algorithms,48 studies of gene-
environment interactions and the building of polygenic risk scores.  
 
In conclusion the ThromboGenomics test is a valuable addition to the diagnostic 
algorithm for patients with a high likelihood of having an inherited BTPD. The results 
provide clinicians with a molecular diagnosis for approximately half of patients allowing 
for more precise prognostication and management of disease and, with cascade testing, 




Variants and pathogenicity (Reinterpretation 2019) have been deposited in ClinVar. 
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The ThromboGenomics TG.V2 and TG.V3 high throughput sequencing test content, 
experimental methods, analysis methods and variant interpretation guidelines.  
 
 TG.V2 TG.V3 
Panel content 
19 Coagulation genes 
8 Thrombotic genes 
53 Platelet genes 
HGMD Pro 2015.2 variants 
 
21 Coagulation genes 
9 Thrombotic genes 
66 Platelet genes 
HGMD Pro 2016.4 variants 
10,000 SNVs  
Region of interest  0.222 Mb 0.275 Mb 
Methods 
DNA fragmentation – 220 bp  
Multiplex – 48 samples 
DNA fragmentation – 350 bp 
Multiplex – 96 samples 
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Figure 1  
Classification of patients using clinical and laboratory phenotypes. 
(A) Classification of 2,396 index patients from the ThromboGenomics, VIBB and PANE 
cohorts into one of five disease classes; thrombotic, platelet count, platelet function, 
coagulation and unexplained bleeding. 











































Diagnostic yield and proportion of novel variants by disease class. 
(A) Diagnostic yield of reported variants for 2,396 index patients for each of the five 
disease classes; thrombotic, platelet count, platelet function, coagulation and 
unexplained bleeding. For patients with more than one reported variant, the most 
pathogenic variant was used in this analysis (n = number of index patients). 
(B) Proportion of reported variants that were novel or known for patients in each disease 

















Gene ranking according to the number of reports per disease class. 
For each disease class, genes were ranked according to number of times they were 
reported. Dashed lines represents, from top to bottom, the 25, 50 and 75 quantiles.  
















Oligogenic variants in patients with thrombotic (red) and coagulation (blue) 
disorders. 
From outside to inside, track 1: amino acid numbering for thrombotic (red) and 
coagulation (blue) genes; lighter shade denote untranslated regions of the 3’ of the F2 
gene and the 5’ of the PROS1 gene; track 2: amino acid  conservation scores; track 3: 
variant frequency in gnomAD (minor allele frequency normalized scale to 1/106); track 4: 
disease causing (red) and questionable disease causing (orange) Human Gene Mutation 
Database variants; track 5 and arcs: reported variants in the 11 thrombotic (red) and 13 
coagulation (blue) patients with the arcs representing oligogenic findings. 
 
 
